CAPhO 2024 Sponsored Symposium AstraZeneca & Daiichi Sankyo - Managing HR+ Metastatic Breast Cancer: Integrating Patient, Tumour, and Drug Regimen Features to Optimize the Patient Journey

This program is intended to educate healthcare professionals on important advances in metastatic breast cancer (mBC) research, and topics related to treatment selection, patient monitoring, and adverse event management. The session will focus on integrating new therapeutic options for patients with HR-positive (HR+) mBC into clinical practice.

Learning Objectives:

• Understand the factors that influence treatment planning and sequencing of new treatment options along the HR+, HER2- and HER2-low patient journeys
• Anticipate potential toxicities associated with AKT-pathway targeted agents and antibody-drug conjugate therapies used for the treatment of HR+, HER2- or HER2-low mBC
• Integrate key teaching points into patient education, focused on patient/caregiver recognition of toxicities and recommended action steps

Sponsored by AstraZeneca and Daiichi Sankyo